Development of Novel β-Carboline/Furylmalononitrile Hybrids as Type I/II Photosensitizers with Chemo-Photodynamic Therapy and Minimal Toxicity.
Xudong XieTiantian SunHeyu PanDongliang JiZhongyuan XuGe GaoJiefei MiaoLei WangYanan ZhangJi LiuYong LingXing SuPublished in: Molecular pharmaceutics (2024)
Chemo-photodynamic therapy is a treatment method that combines chemotherapy and photodynamic therapy and has demonstrated significant potential in cancer treatment. However, the development of chemo-photodynamic therapeutic agents with fewer side effects still poses a challenge. Herein, we designed and synthesized a novel series of β-carboline/furylmalononitrile hybrids 10a - i and evaluated their chemo-photodynamic therapeutic effects. Most of the compounds were photodynamically active and exhibited cytotoxic effects in four cancer cells. In particular, 10f possessed type-I/II photodynamic characteristics, and its 1 O 2 quantum yield increased by 3-fold from pH 7.4 to 4.5. Most interestingly, 10f exhibited robust antiproliferative effects by tumor-selective cytotoxicities and hypoxic-overcoming phototoxicities. In addition, 10f generated intracellular ROS and induced hepatocellular apoptosis, mitochondrial damage, and autophagy. Finally, 10f demonstrated extremely low acute toxicity (LD 50 = 1415 mg/kg) and a high tumor-inhibitory rate of 80.5% through chemo-photodynamic dual therapy. Our findings may provide a promising framework for the design of new photosensitizers for chemo-photodynamic therapy.
Keyphrases
- photodynamic therapy
- oxidative stress
- fluorescence imaging
- cancer therapy
- cell death
- endoplasmic reticulum stress
- dna damage
- diabetic rats
- signaling pathway
- stem cells
- drug delivery
- liver failure
- bone marrow
- radiation therapy
- reactive oxygen species
- hepatitis b virus
- climate change
- combination therapy
- acute respiratory distress syndrome
- human health